Who are CL-108's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tiger Balm, SHR8058 eye drops, Peppermint sweets, Angal, lozenges [menthol],, F# PF-004390 Eye Drops, Placebo with 0.09% menthol gel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cl-108.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CL-108 — Competitive Intelligence Brief

CL-108 (CL-108) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TRPM8 receptor antagonist. Area: Pain management.

phase 3 TRPM8 receptor antagonist TRPM8 Pain management Small molecule Live · refreshed every 30 min

Target snapshot

CL-108 (CL-108) — Charleston Laboratories, Inc. CL-108 is a novel, orally administered, non-opioid, non-sedating, and non-addictive analgesic.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CL-108 TARGET	CL-108	Charleston Laboratories, Inc	phase 3	TRPM8 receptor antagonist	TRPM8
Tiger Balm	Tiger Balm	Apothyx, Co.	marketed	Topical counter-irritant / rubefacient	TRPM8, TRPA1 (transient receptor potential channels)
SHR8058 eye drops	SHR8058 eye drops	Jiangsu HengRui Medicine Co., Ltd.	phase 3	TRPM8 channel antagonist	TRPM8
Peppermint sweets	Peppermint sweets	St. Antonius Hospital	phase 3		TRPM8 receptor
Angal, lozenges [menthol],	Angal, lozenges [menthol],	Sandoz	phase 3	Topical analgesic/local anesthetic	TRPM8 receptor
F# PF-004390 Eye Drops	F# PF-004390 Eye Drops	Johnson & Johnson Consumer Inc. (J&JCI)	phase 3	TRPM8 antagonist	TRPM8
Placebo with 0.09% menthol gel	Placebo with 0.09% menthol gel	GlaxoSmithKline	phase 3	Topical analgesic/counterirritant	TRPM8 (transient receptor potential melastatin 8)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TRPM8 receptor antagonist class)

Charleston Laboratories, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CL-108 — Competitive Intelligence Brief. https://druglandscape.com/ci/cl-108. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab